Physician profile
Timothy Clyde Cox
NPI 1437260650
$8,935.46
in general payments reported to CMS, 2019-2025
71 companies · $2,661 in 2025
The $2,661 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $148 · 2021: $64.99 · 2022: $622 · 2023: $1,980 · 2024: $2,784 · 2025: $2,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,417 · Education: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,416.86 |
| Education | $1,008.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $825.66 | 2019-2025 | Padcev, Xtandi, Xospata |
| Novartis Pharmaceuticals Corporation | $688.64 | 2019-2025 | |
| Janssen Biotech, INC. | $509.20 | 2019-2025 | Rybrevant, Erleada, Darzalex |
| Tempus Ai, INC | $483.87 | 2024-2025 | Xt Cdx |
| Gilead Sciences, INC. | $412.63 | 2019-2025 | Trodelvy |
| Incyte Corporation | $369.08 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Genentech USA, INC. | $355.67 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| E.R. Squibb & Sons, L.L.C. | $339.10 | 2023-2025 | Opdivo, Opdualag |
| Pfizer INC. | $298.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $292.76 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Seagen INC. | $287.87 | 2022-2023 | Tukysa, Padcev, Tivdak |
| Takeda Pharmaceuticals U.S.A., INC. | $277.37 | 2019-2025 | Fruzaqla, Iclusig, Hyqvia |
| Merck Sharp & Dohme LLC | $249.74 | 2023-2025 | Keytruda, Lynparza |
| Genzyme Corporation | $242.41 | 2019-2024 | |
| Eisai INC. | $209.63 | 2022-2025 |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $201.17 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Sirtex Medical INC | $192.79 | 2022 | |
| Tersera Therapeutics LLC | $181.33 | 2019-2025 | Zoladex, Xermelo |
| Daiichi Sankyo INC. | $176.13 | 2023-2025 | Enhertu, Vanflyta, Injectafer |
| Celgene Corporation | $167.08 | 2023-2025 | Reblozyl, Opdivo, Pomalyst |
| Array Biopharma INC | $127.46 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Ipsen Biopharmaceuticals, INC | $124.04 | 2024-2025 | Onivyde, Somatuline Depot |
| Jazz Pharmaceuticals INC. | $118.52 | 2023-2025 | |
| Intuitive Surgical, INC. | $98.51 | 2024 | |
| Pharmaessentia USA Corporation | $92.05 | 2023-2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $81.70 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $78.97 | 2023-2025 | Fotivda |
| Janssen Scientific Affairs, LLC | $78.89 | 2025 | Erleada, Pipeline |
| Beigene USA, INC. | $77.76 | 2024-2025 | Brukinsa, Tevimbra |
| Puma Biotechnology, INC. | $71.61 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $66.18 | 2024-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $64.99 | 2021 | |
| Medical Device Business Services, INC. | $58.32 | 2019 | |
| Rigel Pharmaceuticals, INC. | $53.52 | 2022-2024 | Rezlidhia, Tavalisse |
| Emd Serono, INC. | $53.50 | 2023-2024 | Tepmetko |
| Abbvie INC. | $52.03 | 2023-2025 | Venclexta |
| Glaxosmithkline, LLC. | $46.66 | 2024-2025 | Zejula, Jemperli |
| Sobi, INC | $42.85 | 2023-2024 | |
| Recordati_rare_diseases_inc. | $41.61 | 2024-2025 | Panhematin, Enjaymo |
| Taiho Oncology, INC. | $40.02 | 2019-2022 | |
| Agios Pharmaceuticals, INC. | $38.69 | 2023-2024 | Pyrukynd |
| Blueprint Medicines Corporation | $38.18 | 2023-2024 | Ayvakit |
| Springworks Therapeutics, INC. | $38.02 | 2024-2025 | Ogsiveo |
| Coherus Oncology, INC. | $37.42 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $35.20 | 2023-2024 | Monoferric, Cosela |
| Servier Pharmaceuticals LLC | $35.00 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $31.61 | 2025 | |
| Adc Therapeutics America, INC. | $31.15 | 2024 | |
| Mirati Therapeutics, INC. | $29.95 | 2023-2024 | Krazati |
| Inari Medical, INC. | $26.17 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Apellis Pharmaceuticals, INC. | $24.04 | 2025 | Empaveli |
| Spectrum Pharmaceuticals INC. | $23.43 | 2025 | Rolvedon |
| Alexion Pharmaceuticals, INC. | $21.77 | 2023 | Ultomiris |
| Dendreon Pharmaceuticals LLC | $20.83 | 2025 | Provenge |
| Janssen Pharmaceuticals, INC | $20.31 | 2019 | |
| Myriad Genetic Laboratories, INC. | $20.04 | 2024 | Precisetumor |
| Karyopharm Therapeutics INC. | $19.58 | 2023 | Xpovio |
| Progenics Pharmaceuticals, INC. | $19.28 | 2023 | Pylarify |
| Verastem, INC. | $19.18 | 2019 | |
| G1 Therapeutics, INC. | $18.96 | 2023 | Cosela |
| Cti Biopharma Corp. | $18.59 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.39 | 2023 | Givlaari |
| Amgen INC. | $18.38 | 2023 | Lumakras |
| Emmaus Medical, INC. | $16.93 | 2024 | Endari |
| Foundation Medicine, INC. | $15.19 | 2022 | |
| Deciphera Pharmaceuticals INC. | $15.09 | 2023 | Qinlock |
| Stemline Therapeutics INC. | $14.45 | 2025 | Orserdu |
| Fortovia Therapeutics, INC. | $14.03 | 2020 | |
| Clovis Oncology, INC. | $13.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.